Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== Non-human uses == Menadione, a natural compound sometimes referred to as vitamin K3, is used in the pet food industry because once consumed it is converted to vitamin K2. The US Food and Drug Administration has banned this form from sale as a human dietary supplement because overdoses have been shown to cause allergic reactions, hemolytic anemia, and cytotoxicity in liver cells. 4-amino-2-methyl-1-naphthol is a synthetic menadione analog often called vitamin K5. It has been used as a medicine for vitamin K deficiency. Research with K5 suggests it may inhibit fungal growth in fruit juices.
== Preparation of azide == The aforementioned conversion to acyl azide has been carried out multifariously; Bergmann utilized methyl ester and hydrazide, whereas more recent attempts have designed methods such as: nitrosylation of N-formylaminoacyl hydrazide and subsequent substitution by sodium azide, reaction of a carboxylic acid with diphenyl phosphorazidate, triethylamine, and a hydroxyl component, and reaction between TMS azide and the anhydride of an amino acid.
In 2023, 88% of the Portuguese population lived in urban areas. The capital city, Lisbon, had a population of 658,236 as of 2025. It is part of Lisbon metropolitan area, the biggest metropolitan area of Portugal with 3.4 million people.
=== Pharmacokinetics === The pharmacokinetics of honokiol have been explored in rats and mice; however, further research must be done in humans. Intravenous delivery of 5–10 mg/kg in rodent models has shown a plasma half-life of around 40–60 minutes while intraperitoneal injections of 250 mg/kg had a plasma half-life around 4–6 hours with maximum plasma concentration occurring between 20 and 30 minutes.
Sources: en.wikipedia.org
In geochemistry, geophysics and nuclear physics, primordial nuclides, or primordial isotopes, are nuclides found on Earth that have existed in their current form since before Earth was formed. Primordial nuclides were present in the interstellar medium from which the Solar System was formed, and were formed in the Big Bang, by nucleosynthesis in stars and supernovae followed by mass ejection, by cosmic ray spallation, or from other processes throughout the history of the universe. They are the stable nuclides plus the fraction of the long-lived radionuclides surviving from the primordial solar nebula through planet accretion until the present; 286 such nuclides are known.
Structurally, insulin icodec consists of two peptide chains connected by a disulfide bridge, similar to insulin. However, it includes a C20 fatty diacid-containing side chain to enable strong, reversible albumin binding. Additionally, three amino acid substitutions enhance molecular stability, reduce insulin receptor binding, and slow clearance, collectively extending its duration of action. Insulin icodec received approval for medical use in Canada in March 2024. In the same month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion, recommending marketing authorization for insulin icodec. Subsequently, insulin icodec was approved for medical use in the European Union in May 2024. Insulin icodec is currently marketed by Novo Nordisk under the name Awiqli (pronounced A-week-ly).
Carnivory has evolved multiple times independently in plants in widely separated groups. In three species studied, Cephalotus follicularis, Nepenthes alata and Sarracenia purpurea, there has been convergence at the molecular level. Carnivorous plants secrete enzymes into the digestive fluid they produce. By studying phosphatase, glycoside hydrolase, glucanase, RNAse and chitinase enzymes as well as a pathogenesis-related protein and a thaumatin-related protein, the authors found many convergent amino acid substitutions. These changes were not at the enzymes' catalytic sites, but rather on the exposed surfaces of the proteins, where they might interact with other components of the cell or the digestive fluid. The authors also found that homologous genes in the non-carnivorous plant Arabidopsis thaliana tend to have their expression increased when the plant is stressed, leading the authors to suggest that stress-responsive proteins have often been co-opted in the repeated evolution of carnivory.
North Branch, Minnesota: Specialty Press, 2010. ISBN 978-1-58007-152-9. O'Leary, Michael. USAAF Fighters of World War Two. New York: Sterling Publishing Co., 1986. ISBN 0-7137-1839-0. Oliver, David. P-51 Mustang. Amberley Publishing, 2023. ISBN 9781398110564. Olmsted, Merle. The 357th Over Europe: the 357th Fighter Group in World War II. St. Paul, Minnesota: Phalanx Publishing, 1994. ISBN 0-933424-73-6. Pace, Steve. "Mustang – Thoroughbred Stallion of the Air". Stroud, UK: Fonthill Media, 2012. ISBN 978-1-78155-051-9 Pearcy, Arthur. Lend-Lease Aircraft in World War II. Shrewsbury, UK: Airlife Publishing Ltd., 1996. ISBN 1-85310-443-4. "Pentagon Over the Islands: The Thirty-Year History of Indonesian Military Aviation". Air Enthusiast Quarterly (2): 154–162. n.d. ISSN 0143-5450. Sgarlato, Nico. "Mustang P-51" (in Italian). I Grandi Aerei Storici (Monograph series) N.7, November 2003. Parma, Italy: Delta Editrice. ISSN 1720-0636. Shores, Christopher. "The Allison-engined Mustang: A Fighting Combination". Air Enthusiast Quarterly, No. 2, n.d., pp. 191–206. ISSN 0143-5450 Sims, Edward H. Fighter Tactics and Strategy 1914–1970. Fallbrook, California: Aero publisher Inc., 1980. ISBN 0-8168-8795-0. Smith, J. Richard, Eddie J. Creek and Peter Petrick. On Special Missions: The Luftwaffe's Research and Experimental Squadrons 1923–1945 (Air War Classics). Hersham, Surrey, UK: Classic Publications, 2004. ISBN 1-903223-33-4. Spick, Mike. Fighter Pilot Tactics. The Techniques of Daylight Air Combat. Cambridge, UK: Patrick Stephens, 1983. ISBN 0-85059-617-3. Spick, Mike.
=== Sites for infusion sets === Infusion sets are most commonly placed on the abdomen, in a roughly semicircular area around and below the navel. Other sites include the upper leg, upper buttocks, hips, upper arms and lower back. Insulin absorption may vary from site to site, and therefore medical advice is required.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.